RankingsPricing
  1. US-listed companies
  2. OCULAR THERAPEUTIX, INC
  3. Financials
  4. Capital expenditures

OCULAR THERAPEUTIX, INCOCUL

Market cap
$2.3B
P/E ratio
SummaryFinancials
Period EndCapital expenditures (Million USD)YoY (%)
Dec 31, 2024-1-78.84%
Dec 31, 2023-6+63.85%
Dec 31, 2022-4+211.14%
Dec 31, 2021-1+41.97%
Dec 31, 2020-1-62.42%
Dec 31, 2019-2+18.48%
Dec 31, 2018-2-77.11%
Dec 31, 2017-8+330.02%
Dec 31, 2016-2+7.93%
Dec 31, 2015-2+41.11%
Dec 31, 2014-1

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)